Press Releases
February 5, 2025
NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization
January 21, 2025
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
December 6, 2024
NurExone Announces Promising Preclinical Results in Restoring Vision After Optic Nerve Damage
November 27, 2024
NurExone Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 13, 2024
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
November 1, 2024
NurExone Biologic Closes Final Tranche of Non-Brokered Private Placement and Provides Corporate Update
October 23, 2024
NurExone’s Regenerative Medicine Therapies To Be Recognized at Fall Conferences in the USA
September 26, 2024
NurExone Biologic Announces Private Placement of up to $2M and Closes First Tranche for $1.61M
September 12, 2024